Saturday 17 October 2026 Export TECX’s income statement to Excel — free account

Tectonic Therapeutic, Inc.

In the quarter to June 2026, EPS fell 10.3%, free cash flow fell 46.7% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

20.65 0.65 −3.05%

Follow TECX

Alert me

Market cap: $416.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.18

Total sells 0.65

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	2	—	—	—	—	—	—	—	—
Sell	—	—	—	—	3	1	1	1	—	2	1	—

Insider Ownership 46.37%

Capital & Financial Ratios $m

Market Cap 416.40

Revenue —

Net Income (85.79)

Free Cash Flow (72.38)

Net Debt (227.07)

Current Ratio 22.29

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.75

Past 5Y EPS Growth —

This Y EPS Growth (27.62%)

Next Y EPS Growth (2.84%)

Next Y revenue growth —

Next 5Y EPS Growth (13.91%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 25.20%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	29	141	254	227
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	31	147	257	231

	2023	2024	2025	Q'26
Payables	0	1	1	2
ST’ Debt	—	—	—	—
Other	31	—	—	—
	41	12	10	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(0.24%)	49.40%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(21)	—	—	—
’25	(13)	(15)	(18)	(14)	(60)
’24	(9)	(13)	(20)	(17)	(59)
’23	(20)	0	(8)	(12)	(41)
’22	(28)	(29)	(16)	(24)	(97)
’21	(27)	(20)	(25)	(26)	(98)
’20	(22)	(21)	(25)	(30)	(99)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(22)	—	—	—
’25	(13)	(15)	(18)	(14)	(60)
’24	(9)	(13)	(20)	(17)	(59)
’23	(20)	0	(8)	(12)	(41)
’22	(28)	(29)	(17)	(24)	(97)
’21	(27)	(21)	(25)	(27)	(100)
’20	(23)	(22)	(25)	(31)	(100)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.34)	(1.18)	—	—	—
’25	(0.93)	(1.07)	(1.02)	(1.03)	(4.05)
’24	(10.97)	(4.34)	(1.20)	(0.84)	(6.83)
’23	(0.57)	(8.51)	(7.62)	(0.20)	(33.75)
’22	(0.68)	(0.64)	(0.52)	(0.57)	(2.42)
’21	(0.65)	(0.74)	(0.75)	(0.65)	(2.78)
’20	(0.77)	(0.80)	(1.01)	(0.73)	(3.31)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	171.48	142.20	117.12	38.04	6.72	6.84	1.40	13.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	644.40	342.24	351.84	240.84	49.80	23.16	53.41	61.07
People
People	Employees	—	34	49	85	121	122	78	13	51	60
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(5)	(19)	(46)	(73)	(120)	(119)	(106)	(43)	(58)	(73)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(5)	(19)	(46)	(73)	(120)	(119)	(106)	(43)	(58)	(74)
	Depreciation	—	0	0	1	1	1	1	1	2	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(2.29)	(8.34)	(3.62)	(2.66)	(3.31)	(2.78)	(2.42)	(33.75)	(6.83)	(4.05)
	Cash flow	(1.63)	(7.33)	(2.80)	(2.47)	(2.73)	(2.29)	(2.22)	(32.06)	(6.96)	(3.28)
	Capex	0.00	(0.17)	(0.14)	(0.06)	(0.03)	(0.06)	(0.01)	(0.22)	(0.02)	(0.01)
	Free cash flow	(1.63)	(7.50)	(2.94)	(2.52)	(2.76)	(2.34)	(2.23)	(32.28)	(6.98)	(3.29)
	Book value	(2.25)	(10.35)	9.09	6.78	7.02	3.95	1.72	(66.69)	16.58	13.72
	Shares, m	2	2	13	27	36	43	44	1	8	18
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(3)	(16)	(38)	(68)	(99)	(98)	(97)	(41)	(59)	(60)
	Capex	—	0	(2)	(2)	(1)	(2)	0	0	0	0
	Free cash flow	(3)	(17)	(39)	(69)	(100)	(100)	(97)	(41)	(59)	(60)
Balance, $m
Balance, $m	Working capital	4	4	119	182	251	180	87	(10)	135	248
	Total debt	—	—	—	—	—	15	15	1	0	0
	Net debt	(5)	(6)	(126)	(187)	(260)	(175)	(78)	(28)	(141)	(254)
	Shareholders’ equity	(5)	(23)	122	186	254	169	75	(85)	141	251
Returns, %
Returns, %	ROA	(80.00)	(301.61)	(69.19)	(43.69)	(50.75)	(50.15)	(68.81)	(59.75)	(60.30)	(35.83)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	35.86	135.19	(98.14)	(47.35)	(54.37)	(56.22)	(86.50)	924.30	(206.56)	(37.82)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INDP Indaptus Therapeutics, Inc.	$437.7M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
PRTA Prothena Corporation plc	$436.4M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$433.6M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
PRTCY PureTech Health PLC Sponsored ADR	$424.0M	— (loss-making)	— (loss-making)	−44.60% (below 0%: shrinking)	+66.43% (above 0%: growing)	+19.27% (above 0%: growing)	2.83%	0.00%	Compare
CAPR Capricor Therapeutics, Inc.	$422.7M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
ASMB Assembly Biosciences, Inc.	$418.8M	19.7×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)	Compare
TECX Tectonic Therapeutic, Inc.	$416.4M	— (loss-making)	—	—	n/m	−46.69% (below 0%: shrinking)	0.00%	0.00%
ZURA Zura Bio Limited	$410.2M	— (loss-making)	—	—	n/m	−30.41% (below 0%: shrinking)	—	0.00%	Compare
SPRY ARS Pharmaceuticals, Inc.	$404.8M	— (loss-making)	— (loss-making)	+114.15% (above 0%: growing)	n/m	−53.69% (below 0%: shrinking)	61.83%	(182.62%)	Compare
Median of peers	$423.3M	—	—	−7.92%	—	+0.42%	61.83%	0.00%

All 614 Biotechnology stocks →

Tectonic Therapeutic, Inc. (TECX) key facts

Tectonic Therapeutic, Inc. (TECX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TECX traded at $20.65, a market capitalization of $416.4 million.
Return on equity was −37.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.